What's the optimal steroid taper for a patient with giant cell arteritis?

Induction Dose

• Uncomplicated GCA (no ischaemic features such as visual loss or stroke): initiate prednisolone at 40–60 mg/day orally (or 1 mg/kg/day up to a maximum 60 mg/day per EULAR guidance), maintained for approximately 4 weeks before gradual tapering, per EULAR and BSR guidelines
• Complicated GCA with visual symptoms and ischaemic complications (visual loss, amaurosis fugax) presenting early: pulsed IV methylprednisolone (commonly 0.25–1 g/day × 3 days) should be considered, though the optimal dose remains unspecified in current guidelines; referral for IV therapy should not delay treatment with standard high-dose oral prednisolone
• Maintain initial high dose for 4 weeks minimum (longer if symptoms or inflammatory markers persist) before commencing taper

Taper Schedule (Standard — BSR/EULAR)

Direct RCT evidence comparing the full range of steroid tapering schedules in giant cell arteritis is very limited; available trial data (e.g., GiACTA) have compared specific taper durations rather than the individualized protocols used in practice, so current recommendations are largely expert- and guideline-based.

EULAR targets: ≤15–20 mg/day by 2–3 months after initiation of high-dose glucocorticoid therapy, ≤5 mg/day by 12 months. Typical total treatment duration is at least 1–2 years, but often extends longer; treatment must be individualised based on relapse risk, disease activity, and glucocorticoid tolerability.

Tocilizumab: Shorter Steroid Taper Option

The GiACTA trial (NEJM, 2017) established tocilizumab as a steroid-sparing agent in GCA. Key points:

• Tocilizumab (162 mg SC weekly) + a 26-week prednisolone taper achieved sustained glucocorticoid-free remission at week 52 per protocol taper in ~56% vs ~14–18% with prednisolone alone
• In real-world cohorts, ~60–75% of GCA patients treated with tocilizumab were able to taper off steroids completely within 26 weeks
• Weekly dosing is superior to fortnightly dosing, particularly in relapsing disease
• ACR/VF conditionally recommends tocilizumab + high-dose steroids for all newly diagnosed GCA; EULAR recommends tocilizumab for those with high steroid-toxicity risk or relapsing disease

Monitoring & Relapse

• Monitor ESR and CRP at each visit; dose reductions should only occur in the absence of clinical or laboratory active disease
• CRP is unreliable as a disease-activity marker in patients on tocilizumab (IL-6 receptor blockade directly suppresses CRP); rely on clinical assessment
• Minor relapse (symptoms return without ischaemia): increase prednisolone to last effective dose or 5–15 mg above current dose
• Major relapse (ischaemic symptoms): treat as new-onset GCA (40–60 mg/day ± consider adding/resuming tocilizumab)
• Tapering GC regimens used as maintenance therapy are associated with relapses in more than 40% of patients, mostly during the first two years after diagnosis (Alba et al., 2024)

Adjunct Considerations

• Bone protection: bisphosphonate + calcium + vitamin D for all patients on long-term steroids
• Methotrexate (7.5–15 mg/week): modest steroid-sparing effect; consider at relapse if tocilizumab not accessible
• Monitor regularly for glucocorticoid-related adverse effects during treatment, including diabetes, hypertension, and cataracts, given the prolonged high-dose steroid exposure required for GCA management